Management of Isolated Hypertriglyceridemia with Atorvastatin

Treatment Algorithm

The American College of Cardiology recommends atorvastatin as first-line therapy for patients with moderate hypertriglyceridemia (150-499 mg/dL) and a 10-year ASCVD risk ≥7.5% or poorly controlled major ASCVD risk factors 1, 2
For patients with severe hypertriglyceridemia (≥500 mg/dL), fibrates (fenofibrate 54-160 mg daily) must be initiated first to prevent acute pancreatitis, and atorvastatin can be added once triglycerides fall below 500 mg/dL 1, 3, 4

The American College of Cardiology recommends addressing secondary causes of hypertriglyceridemia, such as uncontrolled diabetes mellitus, hypothyroidism, excessive alcohol consumption, obesity, and metabolic syndrome, before starting atorvastatin 1, 2, 4, 5
Aggressive lifestyle modifications, including a 5-10% weight loss, restricting added sugars, limiting total fat, and engaging in regular aerobic activity, should be implemented concurrently with atorvastatin therapy 4, 5

If triglycerides remain >200 mg/dL after 3 months of maximally tolerated atorvastatin plus optimized lifestyle, prescription omega-3 fatty acids or fenofibrate can be added as adjunctive therapy 4, 5
The American College of Cardiology recommends monitoring fasting lipid panels, liver function tests, and creatine kinase, and reassessing glycemic control in patients with diabetes or prediabetes 5